Three orally active EGFR inhibitors have been tested in clinical trials in recurrent/metastatic SCCHN or in combination with radiotherapy in locoregionally advanced SCCHN (Table 3). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.